Denise Myshko

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.

PBM transparency and data reporting requirements are likely to be part of a larger healthcare bill that Congress will work on this fall.